Provides a full range of vision optic that provides 4D of continuous depth of focus helping patient's with their goal to be spectacle independent.
Optimizes light to provide patients with enhanced image contrast when their vision needs it most: evenly distributing light in photopic conditions (2mm–3mm pupil) and prioritizing distance in mesopic conditions (3.5mm+ pupil).2
1. Data on File. enVista Envy™ US Clinical Study.
2. Data on File, Bausch+Lomb.
3. Data on File. enVista Envy™ Canadian Clinical Study.
The unique fenestration holes of enVista Envy™ simplify lens manipulation during surgery,1 allowing both clockwise and counterclockwise positioning in the capsular bag.
1. Wiley WF. Rotational stability of aberration neutral hydrophobic toric IOL with enhanced delivery characteristics. Presented at: ASCRS Annual Meeting; April 22-26, 2022; Washington, D.C.
Glistening-free material with improved scratch resistance and 25x the hardness of traditional hydrophobic acrylic IOLs.1
1. Elachchabi A, Martin P, Goldberg E, et al. Nanoindentation studies on hydrophobic acrylic IOLs to evaluate surface mechanical properties. Paper presented at: XXV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS); September 8-12, 2007; Stockholm, Sweden.
Efficient lens unfolding, ensuring excellent optic recovery.1
1. enVista Aspire Directions for Use.
360° Posterior Square Edge minimizes contact between the lens and the posterior capsule of the eye, promoting clarity and outstanding defense against Posterior Capsular Opacification (PCO).1,2
1. enVista Aspire Directions for Use.
2. Pai HV, Pathan A, Kamath YS. A comparison of posterior capsular opacification after implantation of three different hydrophobic square edge intraocular lenses. Indian J Ophthalmol. 2019;67(9):1424-1427. doi: 10.4103/ijo.IJO_219_19.
enVista Envy™ is enhanced with proprietary ClearPath technology designed to reduce light scattering.1
1. Data on File, Bausch+Lomb.
Patient reported outcomes: enVista Envy™ enhances your patients’ visual experience in their daily-life activities1
Canadian Clinical Study, enVista Envy™ n=110 patient reported outcomes 6-month post-op, bilateral implantation
1. Data on File. enVista Envy™ Canadian Clinical Study.
A lens with an enviable tolerance to dysphotopsia1, 2*
enVista Envy™ 1, 2*
Type of dysphotopsia | Name% of patients with little to no bothersomeness | % of patients with severe disturbance | ||
---|---|---|---|---|
*Patient reported outcome data at 6-month post-op from enVista Envy™ US clinical study (n=309), enVista Envy™ Canadian clinical study (n=110)
1. Data on File. enVista Envy™ US Clinical Study.
2. Data on File. enVista Envy™ Canadian Clinical Study.
Privacy Policy |
Legal Notice |
Unsubscribe |
Do Not Sell or Share My Personal Information |
Do Not Target |
Limit the Use of My Sensitive Personal Information
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. Except where otherwise indicated. ©2023 Bausch & Lomb Incorporated or its affiliates SRG.0038.USA.22 v4.0